For example, in a recently reported trial [14], two out of ten patients with breast/ovarian cancer vaccinated with HER-2/neu or MUC-1 peptide-pulsed monocyte-derived DCs generated cytotoxic T lymphocytes (CTLs) that were able to kill HLA-A*0201 cell lines expressing these antigens. The gene discussed is ERBB2; the disease is ovarian carcinoma.